Oramed Pharmaceuticals Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · New York, NY
ORMP chart
What traders are saying about $ORMP
Latest postsOramed Pharmaceuticals Inc. news
- Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
Yahoo Finance ·
- ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
Yahoo Finance ·
- Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
Yahoo Finance ·
- Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Yahoo Finance ·
- ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community
Yahoo Finance ·
- Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
Yahoo Finance ·
- June 2026 Penny Stocks To Watch For Potential Growth
Yahoo Finance ·
- ORMP: Strategically Acquiring Interests in Medtech & Technology Companies
Yahoo Finance ·
- Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks
Yahoo Finance ·
- Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
Yahoo Finance ·
- Lifeward Successfully Closes on Strategic Partnership with Oramed
Yahoo Finance ·
- ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value
Yahoo Finance ·
Oramed Pharmaceuticals Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $2.0M | – | $1.3M | $2.7M |
| Net income | $75,324 | -$15,920 | $5,088 | -$36.6M |
| Diluted EPS | $1.50 | $-0.48 | $0.14 | $-0.94 |
| Total assets (year end) | $230.9M | $155.3M | $220.6M | $161.6M |
| Cash and equivalents (year end) | $45.9M | $54.4M | $9.1M | $40.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 8-KCURRENT REPORT
- 10-QQUARTERLY REPORT
- DEF 14APROXY STATEMENT
- 8-KCURRENT REPORT
- 10-QQUARTERLY REPORT
- 8-KCURRENT REPORT
- 10-KANNUAL REPORT
- 8-K8-K
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-K8-K
About Oramed Pharmaceuticals Inc.
- Ticker
- ORMP (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1176309
- Former names
- Integrated Security Technologies, Inc., IGUANA VENTURES LTD
Frequently asked questions
What exchange is Oramed Pharmaceuticals Inc. listed on?
Oramed Pharmaceuticals Inc. trades on the Nasdaq under the ticker symbol ORMP.
What industry is Oramed Pharmaceuticals Inc. in?
Oramed Pharmaceuticals Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Oramed Pharmaceuticals Inc. headquartered?
Oramed Pharmaceuticals Inc.'s business address on file with the SEC is in New York, NY.
When does Oramed Pharmaceuticals Inc.'s fiscal year end?
Oramed Pharmaceuticals Inc.'s fiscal year ends on December 31.
How much revenue did Oramed Pharmaceuticals Inc. report?
Oramed Pharmaceuticals Inc. reported $2.0M in revenue for calendar year 2025, according to its SEC filings.